CVRx, Inc., Receives IDE Approval For Rheos™ Baroreflex Hypertension Therapy™ System Pivotal Trial

MINNEAPOLIS--(BUSINESS WIRE)--CVRx®, Inc., a private medical device company that has developed an implantable medical device to treat high blood pressure, has received a conditional investigational device exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to begin a U.S. pivotal clinical trial that will evaluate the safety and effectiveness of the Rheos™ Baroreflex Hypertension Therapy™ System. Data from this clinical trial is intended to support the Pre-Market Approval (PMA) application for the Rheos System to the FDA.